Sarepta Therapeutics annual ebitda
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sarepta Therapeutics EBITDA Growth & History (SRPT)
Sarepta Therapeutics's calculated EBITDA was −$655.3M for fiscal 2025.
View full Sarepta Therapeutics company overviewSarepta Therapeutics annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$655.3M | −$911.1M | — |
| 2024 | 2024-12-31 | $255.8M | $479.2M | — |
| 2023 | 2023-12-31 | −$223.4M | $270.9M | — |
| 2022 | 2022-12-31 | −$494.3M | −$72.6M | — |
| 2021 | 2021-12-31 | −$421.7M | $115.6M | — |
| 2020 | 2020-12-31 | −$537.3M | $143.8M | — |
| 2019 | 2019-12-31 | −$681.1M | −$349.7M | — |
| 2018 | 2018-12-31 | −$331.4M | −$167.8M | — |
| 2017 | 2017-12-31 | −$163.5M | $97.6M | — |
| 2016 | 2016-12-31 | −$261.1M | −$46.2M | — |
| 2015 | 2015-12-31 | −$214.9M | −$84.8M | — |
| 2014 | 2014-12-31 | −$130.1M | −$41.1M | — |
| 2013 | 2013-12-31 | −$89.0M | −$60.8M | — |
| 2012 | 2012-12-31 | −$28.2M | $6.4M | — |
| 2011 | 2011-12-31 | −$34.6M | −$15.2M | — |
| 2010 | 2010-12-31 | −$19.5M | −$5.3M | — |
| 2009 | 2009-12-31 | −$14.1M | — | — |
Sarepta Therapeutics quarterly ebitda
Q3.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $23.7M | −$102.7M | −81.25% |
| Q1 2026 | 2026-03-31 | $369.0M | $659.4M | — |
| Q4 2025 | 2025-12-31 | −$406.3M | −$578.5M | — |
| Q3 2025 | 2025-09-30 | −$84.9M | −$116.9M | — |
| Q2 2025 | 2025-06-30 | $126.4M | $118.4M | +1476.67% |
| Q1 2025 | 2025-03-31 | −$290.4M | −$334.1M | — |
| Q4 2024 | 2024-12-31 | $172.1M | $136.1M | +378.20% |
| Q3 2024 | 2024-09-30 | $32.0M | $41.9M | — |
| Q2 2024 | 2024-06-30 | $8.0M | $130.7M | — |
| Q1 2024 | 2024-03-31 | $43.6M | $170.4M | — |
| Q4 2023 | 2023-12-31 | $36.0M | $132.3M | — |
| Q3 2023 | 2023-09-30 | −$9.9M | $110.7M | — |
| Q2 2023 | 2023-06-30 | −$122.7M | $78.5M | — |
| Q1 2023 | 2023-03-31 | −$126.8M | −$50.6M | — |
| Q4 2022 | 2022-12-31 | −$96.3M | −$612,000 | — |
| Q3 2022 | 2022-09-30 | −$120.7M | −$96.7M | — |
| Q2 2022 | 2022-06-30 | −$201.2M | −$42.1M | — |
| Q1 2022 | 2022-03-31 | −$76.2M | $66.8M | — |
| Q4 2021 | 2021-12-31 | −$95.7M | $67.8M | — |
| Q3 2021 | 2021-09-30 | −$24.0M | $106.5M | — |
| Q2 2021 | 2021-06-30 | −$159.1M | −$27.2M | — |
| Q1 2021 | 2021-03-31 | −$142.9M | −$31.4M | — |
| Q4 2020 | 2020-12-31 | −$163.4M | $60.1M | — |
| Q3 2020 | 2020-09-30 | −$130.4M | −$13.6M | — |
| Q2 2020 | 2020-06-30 | −$131.9M | $137.3M | — |
| Q1 2020 | 2020-03-31 | −$111.5M | −$40.0M | — |
| Q4 2019 | 2019-12-31 | −$223.6M | −$87.7M | — |
| Q3 2019 | 2019-09-30 | −$116.8M | −$50.3M | — |
| Q2 2019 | 2019-06-30 | −$269.1M | −$168.6M | — |
| Q1 2019 | 2019-03-31 | −$71.5M | −$43.0M | — |
| Q4 2018 | 2018-12-31 | −$135.8M | −$114.8M | — |
| Q3 2018 | 2018-09-30 | −$66.5M | −$23.2M | — |
| Q2 2018 | 2018-06-30 | −$100.6M | −$39.0M | — |
| Q1 2018 | 2018-03-31 | −$28.5M | $9.1M | — |
| Q4 2017 | 2017-12-31 | −$21.0M | $65.7M | — |
| Q3 2017 | 2017-09-30 | −$43.3M | $12.1M | — |
| Q2 2017 | 2017-06-30 | −$61.6M | −$943,000 | — |
| Q1 2017 | 2017-03-31 | −$37.6M | $20.7M | — |
| Q4 2016 | 2016-12-31 | −$86.7M | −$23.6M | — |
| Q3 2016 | 2016-09-30 | −$55.5M | −$5.0M | — |
| Q2 2016 | 2016-06-30 | −$60.6M | −$19.8M | — |
| Q1 2016 | 2016-03-31 | −$58.3M | $2.3M | — |
| Q4 2015 | 2015-12-31 | −$63.1M | −$19.5M | — |
| Q3 2015 | 2015-09-30 | −$50.5M | −$17.8M | — |
| Q2 2015 | 2015-06-30 | −$40.8M | −$11.5M | — |
| Q1 2015 | 2015-03-31 | −$60.6M | −$36.0M | — |
| Q4 2014 | 2014-12-31 | −$43.6M | −$11.0M | — |
| Q3 2014 | 2014-09-30 | −$32.6M | −$8.0M | — |
| Q2 2014 | 2014-06-30 | −$29.3M | −$12.5M | — |
| Q1 2014 | 2014-03-31 | −$24.6M | −$9.6M | — |
| Q4 2013 | 2013-12-31 | −$32.6M | −$22.6M | — |
| Q3 2013 | 2013-09-30 | −$24.6M | −$18.1M | — |
| Q2 2013 | 2013-06-30 | −$16.8M | −$11.6M | — |
| Q1 2013 | 2013-03-31 | −$15.0M | −$8.4M | — |
| Q4 2012 | 2012-12-31 | −$9.9M | −$1.5M | — |
| Q3 2012 | 2012-09-30 | −$6.5M | $4.5M | — |
| Q2 2012 | 2012-06-30 | −$5.2M | $4.7M | — |
| Q1 2012 | 2012-03-31 | −$6.5M | −$1.2M | — |
| Q4 2011 | 2011-12-31 | −$8.5M | — | — |
| Q3 2011 | 2011-09-30 | −$11.0M | −$7.6M | — |
| Q2 2011 | 2011-06-30 | −$9.9M | — | — |
| Q1 2011 | 2011-03-31 | −$5.3M | — | — |
| Q3 2010 | 2010-09-30 | −$3.4M | — | — |
Sarepta Therapeutics ebitda trends
Over the last five fiscal years, Sarepta Therapeutics's ebitda decreased from −$537.3M to −$655.3M, a change of −$118.0M. The latest reported quarter, Q2 2026, shows $23.7M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sarepta Therapeutics source filings ↗Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...
